Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

out CYT003-QbG10

CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the ImmunodrugTM QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed to induce a potent Th1 type immune response in order to suppress an “allergic” Th2 type immune response. As initial clinical observations indicate, CYT003-QbG10 could thereby act by an allergen-independent mechanism of action so that it has potential as a causal and disease-modifying treatment for a broad range of different allergic diseases. CYT003-QbG10 is currently being studied in several clinical trials for the treatment of allergic rhinitis, asthma and atopic dermatitis.

About allergic diseases

Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. It is an exaggerated reaction by the patient’s immune system to a normally harmless substance such as various environmental proteins present in pollen, animal excrements, or food. According to the World Health Organization, more than 20% of the world population suffers from allergic diseases (WHO, 2002).

Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) is very common and affects 15-20% of the European population (WHO Europe, 2003). Three general approaches are commonly being pursued to relieve the symptoms of allergic diseases: avoidance of the allergen, prescription of medication that targets disease symptoms, and conventional immunotherapy, also known as desensitization. The latter is the only disease-modifying treatment available, however, it is applicable only for some defined allergies, is time-consuming (3-5 years) and inconvenient for the patients. T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... a special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates ... continue highlighting the success of the prescription drug benefit, commonly referred to as Part ... infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... 15 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... the sale of 4,229,000 of its common shares to Commerce ... approximately $6.3 million , or approximately $1.49 ... Commerce Court.  Poniard intends to use the approximately $6.1 ...
... 15 At this year,s annual meeting of ... in Atlanta , Royal Philips Electronics ( ... cardiology patient care by highlighting a range of technology ... intuitive information management systems, new temperature modulation therapies, solutions ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces $6.3 Million Financing 2Poniard Pharmaceuticals Announces $6.3 Million Financing 3Poniard Pharmaceuticals Announces $6.3 Million Financing 4Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 2Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 3Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 4Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 5Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 6Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 7Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 8Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 9
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
(Date:8/1/2015)... ... 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair ... first small business donation to kick off the campaign for healing and Well-Being. , ... includes a complete line of raw, organic hair care products, as well as her ...
(Date:7/31/2015)... New York, New York (PRWEB) , ... July 31, 2015 , ... ... started to strut their stuff, Super-Sod debuted their new type of sod called ... with registered trademark application in process. , To commemorate introduction of this new type ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by ... predictive health analytics , Jvion continues to disrupt the predictive analytic and ... that targets patient and population level illness to drive prevention and better health ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation ... Conference Center. The medical community, social workers, law enforcement, and government officials are ... in the effort to better understand and combat sex trafficking. Lead by sex ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... with HIV/AIDS have opposed a patent application filed by ... combination AIDS drug on the grounds that it would ... by the Lawyers' Collective HIV/AIDS Unit, the Indian Network ... of Positive People Thursday officially submitted their opposition to ...
... from Duke University Medical Center and John Hopkins University ... signaling pathway that plays a vital role in the ... injury lead to the development of liver cancer. ... in immature, stem-like liver cells. This discovery could lead ...
... to propagate a new method of sex education for youngsters ... with the China Family Planning Association, said: 'Puberty and child-bearing ... is lagging behind.' ,China now has more than ... million become sexually mature each year. ,Education ...
... an alarming rise in obesity among city kids in Britain, increasing ... 37% of the urban kids really walk to school as compared ... of the kids spend almost 4 hrs sedentarily, watching television or ... of Type 2 diabetes, which was common only in the above ...
... using tissue cultures suggests, that a pain killing medication helps ... to a common form of breast cancer. The name of ... labs experiments on breast cancer cells, scientists found that derivatives ... in estrogen-dependent breast cancer. This form of cancer is the ...
... Hopkins joined the aid efforts by identifying more than ... // The devastating natural disaster, which hit Louisiana and ... Even though most of victims were identified by their ... analysis. ,Using experience gained in DNA analysis of ...
Cached Medicine News:Health News:HIV Patients Opposes Patenting Of AIDS Drug 2Health News:Unchecked Cellular Repair Pathway Causes Liver Cancer 2Health News:Pain-killer Drug Can Help Fight Breast Cancer 2Health News:Genetic Experts of Hopkins Assists In Identifying Hurricane Katrina Victims 2Health News:Genetic Experts of Hopkins Assists In Identifying Hurricane Katrina Victims 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: